From Genome Editing Innovation To Therapeutic Reality

A Q&A with Tom Foti, VP, Scientific Partnerships

This Q&A with Tom Foti, Vice President of Scientific Partnerships, explores how genome editing is evolving from a promising research tool into a therapeutic reality. As developers move beyond first-generation CRISPR-Cas9 systems, emerging technologies such as base editing, prime editing, recombinases, and RNA-targeted approaches are creating new opportunities to address genetic diseases with greater precision and control.

The discussion examines the key factors influencing technology selection, from therapeutic objectives and delivery strategies to safety considerations and target accessibility. It also highlights the challenges that continue to shape the field, including delivery limitations, manufacturing scalability, regulatory expectations, and reimbursement pathways. Looking ahead, advances in delivery technologies, quality control, and translational experience are expected to expand the range of treatable conditions and support broader clinical adoption.

Gain practical insight into the scientific, operational, and regulatory developments that will help define the next decade of genome editing innovation.